Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "NITIE"

922 News Found

Novo Medi Sciences launches ‘G.A.U.R.I.’ to drive immunization for underprivileged girls
News | February 06, 2026

Novo Medi Sciences launches ‘G.A.U.R.I.’ to drive immunization for underprivileged girls

Novo Medi Sciences aims to reach millions nationwide and provide NEXIPOX PLUS vaccination against chickenpox to thousands of underprivileged girl children


Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan
Policy | February 01, 2026

Budget 2026 -27: Pharma sector cheers Rs. 10,000 crore Biopharma plan

The Union Budget makes a clear and timely choice by placing biopharma at the centre of India’s next manufacturing wave


Eli Lilly announces $3.5 billion Pennsylvania manufacturing hub
News | January 31, 2026

Eli Lilly announces $3.5 billion Pennsylvania manufacturing hub

The facility will bring 850 high-value jobs to the region, including engineers, scientists, operations personnel, and lab technicians


AstraZeneca pledges $15 billion investment in China through 2030
News | January 30, 2026

AstraZeneca pledges $15 billion investment in China through 2030

UK Prime Minister Keir Starmer praised the initiative, saying: “Unlocking opportunities for British businesses across the globe and delivering for working people back home is always the driving force behind my international engagements."


Wanbury unveils API facility in Tanuku, targets Rs. 100 crore revenue
News | January 30, 2026

Wanbury unveils API facility in Tanuku, targets Rs. 100 crore revenue

The Tanuku facility will focus on the production of key therapeutic APIs, including Anti-Tussive, Anti-Coagulant (Blood Thinner), Anaesthetic, and Antidepressant molecules


Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience
News | January 30, 2026

Siegfried expands US footprint with major acquisition of Noramco & Extractas Bioscience

The deal brings three high-quality small-molecule drug substance sites into Siegfried’s portfolio